CN101248019B - 部分脱乙酰化壳多糖衍生物的组合物 - Google Patents
部分脱乙酰化壳多糖衍生物的组合物 Download PDFInfo
- Publication number
- CN101248019B CN101248019B CN2006800285048A CN200680028504A CN101248019B CN 101248019 B CN101248019 B CN 101248019B CN 2006800285048 A CN2006800285048 A CN 2006800285048A CN 200680028504 A CN200680028504 A CN 200680028504A CN 101248019 B CN101248019 B CN 101248019B
- Authority
- CN
- China
- Prior art keywords
- chitin
- bone
- chos
- partially deacetylated
- shell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920002101 Chitin Polymers 0.000 title claims abstract description 133
- 239000000203 mixture Substances 0.000 title abstract description 83
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 120
- 238000000034 method Methods 0.000 claims abstract description 109
- 229920000642 polymer Polymers 0.000 claims abstract description 75
- 239000000126 substance Substances 0.000 claims abstract description 45
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 30
- 230000006196 deacetylation Effects 0.000 claims abstract description 23
- 238000003381 deacetylation reaction Methods 0.000 claims abstract description 23
- 239000012620 biological material Substances 0.000 claims abstract description 21
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 16
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims abstract description 8
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229950006780 n-acetylglucosamine Drugs 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 71
- 108010022172 Chitinases Proteins 0.000 claims description 40
- 102000012286 Chitinases Human genes 0.000 claims description 40
- 210000001519 tissue Anatomy 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 34
- 230000008569 process Effects 0.000 claims description 30
- 239000001506 calcium phosphate Substances 0.000 claims description 29
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 29
- 235000011010 calcium phosphates Nutrition 0.000 claims description 29
- 239000000463 material Substances 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 22
- 230000004071 biological effect Effects 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 10
- 239000010408 film Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- -1 monocarboxylic acid organic acid salt Chemical class 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 230000000630 rising effect Effects 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical group [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 150000002337 glycosamines Chemical class 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 239000003929 acidic solution Substances 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 101710194948 Protein phosphatase PhpP Proteins 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 235000011132 calcium sulphate Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- HWGNBUXHKFFFIH-UHFFFAOYSA-I pentasodium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O HWGNBUXHKFFFIH-UHFFFAOYSA-I 0.000 claims description 3
- 239000008279 sol Substances 0.000 claims description 3
- 150000003628 tricarboxylic acids Chemical group 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 239000004088 foaming agent Substances 0.000 claims description 2
- 230000023597 hemostasis Effects 0.000 claims description 2
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 claims description 2
- 238000000247 postprecipitation Methods 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 230000017423 tissue regeneration Effects 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 2
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 239000002243 precursor Substances 0.000 abstract description 12
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract 1
- 229960002442 glucosamine Drugs 0.000 abstract 1
- 238000011084 recovery Methods 0.000 description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- 230000000694 effects Effects 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 32
- 210000000845 cartilage Anatomy 0.000 description 28
- 239000000523 sample Substances 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 239000003513 alkali Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000005227 gel permeation chromatography Methods 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 210000000544 articulatio talocruralis Anatomy 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 17
- 235000011121 sodium hydroxide Nutrition 0.000 description 17
- 206010061218 Inflammation Diseases 0.000 description 16
- 238000004108 freeze drying Methods 0.000 description 16
- 230000004054 inflammatory process Effects 0.000 description 16
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 16
- 238000006460 hydrolysis reaction Methods 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000007062 hydrolysis Effects 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- 238000000108 ultra-filtration Methods 0.000 description 12
- 238000010494 dissociation reaction Methods 0.000 description 11
- 230000005593 dissociations Effects 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000005457 optimization Methods 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 206010003246 arthritis Diseases 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000003053 toxin Substances 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- 101710116747 Chitinase A Proteins 0.000 description 8
- 101710202612 Endochitinase A Proteins 0.000 description 8
- 208000006735 Periostitis Diseases 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 8
- 230000021736 acetylation Effects 0.000 description 8
- 238000006640 acetylation reaction Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 230000035194 endochondral ossification Effects 0.000 description 8
- 239000007943 implant Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 206010025482 malaise Diseases 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 210000003460 periosteum Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 210000003967 CLP Anatomy 0.000 description 7
- 206010039361 Sacroiliitis Diseases 0.000 description 7
- 239000012491 analyte Substances 0.000 description 7
- 229920001222 biopolymer Polymers 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000001819 mass spectrum Methods 0.000 description 7
- 239000002516 radical scavenger Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000001612 chondrocyte Anatomy 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 238000005553 drilling Methods 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 101150011812 AADAC gene Proteins 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 208000018937 joint inflammation Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- PBLZLIFKVPJDCO-UHFFFAOYSA-N omega-Aminododecanoic acid Natural products NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 241001111421 Pannus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 230000003196 chaotropic effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 101150038575 clpS gene Proteins 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- HJVCHYDYCYBBQX-HLTLHRPFSA-N (2s,3s,4e,6e,8s,9s)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid Chemical compound OC(=O)[C@@H](C)[C@@H](N)/C=C/C(/C)=C/[C@H](C)[C@@H](OC)CC1=CC=CC=C1 HJVCHYDYCYBBQX-HLTLHRPFSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010007710 Cartilage injury Diseases 0.000 description 3
- 102000002734 Collagen Type VI Human genes 0.000 description 3
- 108010043741 Collagen Type VI Proteins 0.000 description 3
- 241000238557 Decapoda Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 239000006035 Tryptophane Substances 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000001736 capillary Anatomy 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000010612 desalination reaction Methods 0.000 description 3
- 238000002086 displacement chromatography Methods 0.000 description 3
- IHSPMDXQWYKHOA-UHFFFAOYSA-N dodecyl 2-(dimethylamino)acetate Chemical compound CCCCCCCCCCCCOC(=O)CN(C)C IHSPMDXQWYKHOA-UHFFFAOYSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 231100000284 endotoxic Toxicity 0.000 description 3
- 230000002346 endotoxic effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- OMNKZBIFPJNNIO-UHFFFAOYSA-N n-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=O)CC(C)(C)NC(=O)C=C OMNKZBIFPJNNIO-UHFFFAOYSA-N 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 229920002959 polymer blend Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000012882 sequential analysis Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 102100038196 Chitinase-3-like protein 1 Human genes 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 2
- 241001484259 Lacuna Species 0.000 description 2
- 102000004317 Lyases Human genes 0.000 description 2
- 108090000856 Lyases Proteins 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- PFZKWTWCVGDJQC-AOMJWMKZSA-N N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S,6R)-3-Acetamido-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 PFZKWTWCVGDJQC-AOMJWMKZSA-N 0.000 description 2
- 229920002274 Nalgene Polymers 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000238371 Sepiidae Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 210000001025 archicortex Anatomy 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000003559 hypertrophic chondrocyte Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 230000002138 osteoinductive effect Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000024287 Areas Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000017234 Bone cyst Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 208000005917 Exostoses Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000002203 Phidippus borealis Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000004973 alkali metal peroxides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910001576 calcium mineral Inorganic materials 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000001142 dicarboxylic acid group Chemical group 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000035616 enchondral ossification Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001869 matrix assisted laser desorption--ionisation mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000030248 negative regulation of fibroblast proliferation Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002957 persistent organic pollutant Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 238000000710 polymer precipitation Methods 0.000 description 1
- 238000010094 polymer processing Methods 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000012492 regenerant Substances 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 1
- MWNQXXOSWHCCOZ-UHFFFAOYSA-L sodium;oxido carbonate Chemical compound [Na+].[O-]OC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000028528 solitary bone cyst Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/009—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Surgery (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Sustainable Development (AREA)
- Immunology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS7895 | 2005-06-14 | ||
| IS7895 | 2005-06-14 | ||
| PCT/IS2006/000013 WO2006134614A1 (en) | 2005-06-14 | 2006-06-14 | Compositions of partially deacetylated chitin derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101248019A CN101248019A (zh) | 2008-08-20 |
| CN101248019B true CN101248019B (zh) | 2012-12-26 |
Family
ID=36685789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006800285048A Active CN101248019B (zh) | 2005-06-14 | 2006-06-14 | 部分脱乙酰化壳多糖衍生物的组合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9078949B2 (enExample) |
| EP (1) | EP1917218B1 (enExample) |
| JP (2) | JP5632125B2 (enExample) |
| KR (1) | KR101569751B1 (enExample) |
| CN (1) | CN101248019B (enExample) |
| AU (1) | AU2006257177A1 (enExample) |
| BR (1) | BRPI0612034A2 (enExample) |
| CA (1) | CA2611453C (enExample) |
| DK (1) | DK1917218T3 (enExample) |
| HU (1) | HUE035956T2 (enExample) |
| LT (1) | LT1917218T (enExample) |
| MX (2) | MX375577B (enExample) |
| NO (2) | NO344086B1 (enExample) |
| NZ (1) | NZ565022A (enExample) |
| RU (1) | RU2421467C2 (enExample) |
| SI (1) | SI1917218T1 (enExample) |
| WO (1) | WO2006134614A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS6085A (is) | 2001-09-26 | 2003-03-27 | Genis Ehf. | Lyfjablanda með kítósan óligómerum |
| US9034348B2 (en) | 2006-12-11 | 2015-05-19 | Chi2Gel Ltd. | Injectable chitosan mixtures forming hydrogels |
| EP1958639A1 (en) | 2007-02-14 | 2008-08-20 | Polichem S.A. | Use of chitosans for the treatment of nail inflammatory diseases |
| US10201490B2 (en) | 2007-02-14 | 2019-02-12 | Polichem Sa | Use of chitosans for the treatment of nail inflammatory diseases |
| JP5746617B2 (ja) * | 2008-06-11 | 2015-07-08 | チ２ジェル リミテッドＣｈｉ２Ｇｅｌ Ｌｔｄ． | キトサン混合物を形成する注入可能なヒドロゲル |
| WO2010007631A1 (en) * | 2008-07-18 | 2010-01-21 | Genis Ehf. | New composition for treating autoimmune disorders |
| CN102417550B (zh) * | 2010-09-28 | 2014-04-30 | 扬州鸿信生物制品有限公司 | 一种甲壳素生产设备 |
| WO2012145626A1 (en) * | 2011-04-22 | 2012-10-26 | Ancora Pharmaceuticals Inc. | Synthetic oligosaccharides for staphylococcus vaccine |
| US10130654B2 (en) * | 2011-05-24 | 2018-11-20 | Hangli Biosciences Co., Ltd. | Method of inducing osteogensis and promoting osseointegration around an implant |
| GB201205174D0 (en) * | 2012-03-23 | 2012-05-09 | Medtrade Products Ltd | Process for producing low endotoxin chitosan |
| CN104470550A (zh) * | 2012-04-23 | 2015-03-25 | 杰尼斯公共有限公司 | 作为骨移植替代物的含有部分脱乙酰壳多糖的自硬化生物活性接合剂组合物 |
| US20160017062A1 (en) | 2013-03-12 | 2016-01-21 | Wellstat Vaccines, Llc | Antibodies targeted to fungal cell wall polysaccharides |
| GB201309606D0 (en) * | 2013-05-29 | 2013-07-10 | Medtrade Products Ltd | Process for producing low endotoxin chitosan |
| GB201309607D0 (en) * | 2013-05-29 | 2013-07-10 | Medtrade Products Ltd | Process for producing low endotoxin chitosan |
| GB2514592A (en) | 2013-05-30 | 2014-12-03 | Medtrade Products Ltd | Degradable haemostat composition |
| FR3016882A1 (fr) | 2014-01-30 | 2015-07-31 | Sofradim Production | Procede de preparation de chitosane a haut degre d’acetylation |
| JP6512630B2 (ja) * | 2015-02-26 | 2019-05-15 | オルガノ株式会社 | セレン及び／またはヒ素の濃縮方法及び分析方法並びに装置 |
| CN108114321A (zh) * | 2017-12-29 | 2018-06-05 | 广州军区广州总医院 | 一种抗骨巨细胞瘤壳聚糖-纳米羟基磷灰石支架、其制备方法及应用 |
| CN109529105A (zh) * | 2018-10-04 | 2019-03-29 | 南京航空航天大学溧水仿生产业研究院有限公司 | 仿生人工骨材料的制备方法 |
| WO2020186021A1 (en) * | 2019-03-13 | 2020-09-17 | Virginia Commonwealth University | Method for forming flexible and biodegradable structures from low molecular weight chitin biopolymers |
| WO2021195452A1 (en) * | 2020-03-26 | 2021-09-30 | Subhra Mohapatra | Use of oligochitosans and derivatives thereof for neutralizing viral agents |
| JP7602224B2 (ja) * | 2020-05-15 | 2024-12-18 | 京都府公立大学法人 | 非晶性キチンを含む創傷治癒材 |
| CN111803714B (zh) * | 2020-07-29 | 2021-12-21 | 陕西科技大学 | 一种综合酸-碱溶剂体系的壳聚糖骨修复支架及其制备方法 |
| CN112341551A (zh) * | 2020-11-05 | 2021-02-09 | 广东广纳安疗科技有限公司 | 一种具有超低内毒素的壳聚糖类物质及其制备方法 |
| CN112724273B (zh) * | 2021-01-26 | 2022-02-22 | 焦点生物医药有限公司 | 一种高分子量银耳多糖的提取及制备方法 |
| EP4122961A1 (en) * | 2021-07-20 | 2023-01-25 | Westfälische Wilhelms-Universität Münster | Chitosan oligomers and uses thereof |
| KR20240122463A (ko) * | 2021-12-20 | 2024-08-12 | 제니스 에이치에프 | 부분 탈아세틸화 키토산을 포함하는 생활성 코팅을 갖는 임플란트 |
| CN114533967B (zh) * | 2022-03-30 | 2023-01-03 | 江苏益通生物科技有限公司 | 一种脱乙酰壳聚糖神经导管及其制备方法 |
| JP2025526752A (ja) * | 2022-08-11 | 2025-08-15 | ジーニス エイチエフ． | ３ｄプリントされた生体活性スキャホールド |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2795579A (en) * | 1953-10-09 | 1957-06-11 | Warner Lambert Pharmaceutical | Process for purification of chitosan by means of the salicylic acid salt thereof |
| US5077052A (en) * | 1988-11-30 | 1991-12-31 | Rhone-Poulenc Sante | Chitosan derivatives useful in compositions for coating feedstuff additives intended for ruminants |
| CN1554267A (zh) * | 2003-12-23 | 2004-12-15 | 孝感学院 | 一种制备水溶性壳聚糖的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2814701B2 (ja) * | 1990-06-04 | 1998-10-27 | 味の素株式会社 | 水容性部分脱アセチル化キチンの製造法 |
| JP3181337B2 (ja) * | 1991-09-13 | 2001-07-03 | ピアス株式会社 | キトサンオリゴ糖混合物の製造方法、及びキチンオリゴ糖混合物の製造方法 |
| RU2065447C1 (ru) * | 1992-11-30 | 1996-08-20 | Владимир Петрович Голицин | Способ получения хитозана |
| KR970008132B1 (ko) | 1993-02-08 | 1997-05-21 | 전동원 | 생체 임상의학용 키틴 및 키토산 제조방법 |
| JP3118423B2 (ja) * | 1996-08-30 | 2000-12-18 | ツヤック株式会社 | 水溶性の部分アセチル化キトサン液の製造方法 |
| JP2990248B2 (ja) * | 1997-06-18 | 1999-12-13 | 鳥取県 | 非晶質の水溶性部分脱アセチル化キチンの製造方法 |
| JPH11276189A (ja) * | 1998-03-30 | 1999-10-12 | Tottori Prefecture | 非晶質の水溶性部分脱アセチル化キチンを基質とする酵素によるオリゴ糖の製造方法 |
| US20030158302A1 (en) * | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
| JP3653626B2 (ja) * | 2000-01-13 | 2005-06-02 | 独立行政法人科学技術振興機構 | 有機・無機交互多重積層複合体 |
| JP4669932B2 (ja) * | 2000-05-02 | 2011-04-13 | 学校法人日本大学 | 生体材料用組成物及びその硬化体 |
| WO2002059395A2 (en) * | 2000-12-28 | 2002-08-01 | The Board Of Regents Of The University Of Nebraska | Electrolytic deposition of coatings for prosthetic metals and alloys |
| NO20015986D0 (no) * | 2001-08-02 | 2001-12-06 | Einar J Mustaparta | Produktet chitosan, samt fremstillingsmetode og anvendelse av chitosan |
| IS6085A (is) * | 2001-09-26 | 2003-03-27 | Genis Ehf. | Lyfjablanda með kítósan óligómerum |
| JP3755004B2 (ja) * | 2003-07-01 | 2006-03-15 | 独立行政法人物質・材料研究機構 | キチン誘導体−リン酸カルシウム複合体繊維とその製造方法 |
| DE202008005046U1 (de) | 2008-04-11 | 2008-07-03 | Design Ballendat Gmbh | Tisch mit verschwenkbarem Bügelfuß |
-
2006
- 2006-06-14 JP JP2008516507A patent/JP5632125B2/ja active Active
- 2006-06-14 AU AU2006257177A patent/AU2006257177A1/en not_active Abandoned
- 2006-06-14 DK DK06745229.2T patent/DK1917218T3/en active
- 2006-06-14 BR BRPI0612034-2A patent/BRPI0612034A2/pt not_active Application Discontinuation
- 2006-06-14 LT LTEP06745229.2T patent/LT1917218T/lt unknown
- 2006-06-14 CA CA2611453A patent/CA2611453C/en active Active
- 2006-06-14 CN CN2006800285048A patent/CN101248019B/zh active Active
- 2006-06-14 MX MX2015012065A patent/MX375577B/es unknown
- 2006-06-14 EP EP06745229.2A patent/EP1917218B1/en active Active
- 2006-06-14 NZ NZ565022A patent/NZ565022A/en unknown
- 2006-06-14 HU HUE06745229A patent/HUE035956T2/en unknown
- 2006-06-14 KR KR1020087001087A patent/KR101569751B1/ko active Active
- 2006-06-14 RU RU2008101385/05A patent/RU2421467C2/ru active
- 2006-06-14 MX MX2007015767A patent/MX336736B/es unknown
- 2006-06-14 SI SI200632196T patent/SI1917218T1/sl unknown
- 2006-06-14 US US11/922,014 patent/US9078949B2/en active Active
- 2006-06-14 WO PCT/IS2006/000013 patent/WO2006134614A1/en not_active Ceased
-
2008
- 2008-01-14 NO NO20080240A patent/NO344086B1/no unknown
-
2014
- 2014-07-10 JP JP2014142045A patent/JP6293005B2/ja active Active
-
2015
- 2015-06-11 US US14/736,984 patent/US20160002360A1/en not_active Abandoned
-
2017
- 2017-12-27 US US15/855,884 patent/US20180186899A1/en not_active Abandoned
-
2019
- 2019-07-30 NO NO20190933A patent/NO20190933A1/no not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2795579A (en) * | 1953-10-09 | 1957-06-11 | Warner Lambert Pharmaceutical | Process for purification of chitosan by means of the salicylic acid salt thereof |
| US5077052A (en) * | 1988-11-30 | 1991-12-31 | Rhone-Poulenc Sante | Chitosan derivatives useful in compositions for coating feedstuff additives intended for ruminants |
| CN1554267A (zh) * | 2003-12-23 | 2004-12-15 | 孝感学院 | 一种制备水溶性壳聚糖的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1917218A1 (en) | 2008-05-07 |
| KR20080036580A (ko) | 2008-04-28 |
| KR101569751B1 (ko) | 2015-11-19 |
| NO20080240L (no) | 2008-03-06 |
| MX336736B (es) | 2016-01-29 |
| SI1917218T1 (sl) | 2017-12-29 |
| JP2008544014A (ja) | 2008-12-04 |
| US20180186899A1 (en) | 2018-07-05 |
| HUE035956T2 (en) | 2018-05-28 |
| RU2008101385A (ru) | 2009-07-20 |
| JP5632125B2 (ja) | 2014-11-26 |
| CA2611453A1 (en) | 2006-12-21 |
| US9078949B2 (en) | 2015-07-14 |
| MX375577B (es) | 2025-03-06 |
| JP2014221905A (ja) | 2014-11-27 |
| US20160002360A1 (en) | 2016-01-07 |
| NO20190933A1 (no) | 2008-03-06 |
| EP1917218B1 (en) | 2017-05-17 |
| LT1917218T (lt) | 2017-11-27 |
| JP6293005B2 (ja) | 2018-03-14 |
| AU2006257177A1 (en) | 2006-12-21 |
| DK1917218T3 (en) | 2017-09-11 |
| CA2611453C (en) | 2015-10-06 |
| US20090281058A1 (en) | 2009-11-12 |
| RU2421467C2 (ru) | 2011-06-20 |
| NZ565022A (en) | 2011-04-29 |
| CN101248019A (zh) | 2008-08-20 |
| BRPI0612034A2 (pt) | 2012-08-28 |
| WO2006134614A1 (en) | 2006-12-21 |
| NO344086B1 (no) | 2019-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101248019B (zh) | 部分脱乙酰化壳多糖衍生物的组合物 | |
| KR101874819B1 (ko) | 세포외 기질 재료로부터의 생리활성 조직 손상 치료 재료 | |
| CN106039416B (zh) | 壳聚糖—丝胶蛋白复合生物支架及其制备方法和应用 | |
| Dang et al. | Decanoic acid functionalized chitosan: Synthesis, characterization, and evaluation as potential wound dressing material | |
| CN106496430B (zh) | 具有生物相容性的抗微生物高分子 | |
| Zheng et al. | Carp scales derived double cross-linking hydrogels achieve collagen peptides sustained-released for bone regeneration | |
| Ray et al. | Enhanced bone regeneration using Antheraea mylitta silk fibroin and chitosan based scaffold: in-vivo and in-vitro study | |
| Cabral et al. | Characterization of the in vivo host response to a bi‐labeled chitosan‐dextran based hydrogel for postsurgical adhesion prevention | |
| Chen et al. | Sulfated alginate based complex for sustained calcitonin delivery and enhanced osteogenesis | |
| CN116082453B (zh) | 一种用于明胶酶酶切响应的多肽及含多肽的骨缺损修复支架 | |
| Bombaldi de Souza et al. | Xanthan Gum for Regenerative Medicine | |
| CN110665060A (zh) | 一种骨修复材料及其制备方法和应用 | |
| KR100735675B1 (ko) | 저분자화 및 친수성을 높여 콜라겐의 유효이용율을향상시키기 위한 제조방법 | |
| Sunarso et al. | Effect of crosslinking to the mechanical property of apatite gelatin hybrid for bone substitution purposes | |
| KR102795186B1 (ko) | 초임계 이산화탄소 공정 기반 생체 적합성이 증진된 탈세포 기질 제조 방법 | |
| Raj | Chitin biopolymer in tissue engineering | |
| KR20130052878A (ko) | 당뇨 개선 기능을 가지는 실크 펩타이드 조성물 | |
| CN114891238A (zh) | 一种多酚小分子诱导的副肌球蛋白水凝胶的制备方法及其应用 | |
| CN120098888A (zh) | 一种羊皮去细胞蛋白基质胶的制备方法 | |
| KR20130052910A (ko) | 고콜레스테롤증 및 고지혈증 개선의 복합 기능을 가지는 실크 펩타이드 조성물 | |
| Orluvosu | In vivo investigation of new chitosan-hydroxyapatite bone scaffolds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |